1yr
Lipid Management Connect
1yr
Effects of exercise and dietary interventions on asprosin, leptin, and lipid metabolism in males with abdominal obesity, a randomized controlled trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39548289/
Addressing abdominal obesity requires multifaceted strategies, with physical activity and diet playing a pivotal role. The objective of this study was to assess alterations in body composition, adipokine concentrations, insulin...
In men with abdominal obesity, combining exercise with a high-protein, low-glycemic diet produced greater reductions in body fat, adipokines, insulin resistance, and cholesterol, outperforming exercise alone.
1yr
Nutrition and Lifestyle Interventions in Managing Dyslipidemia and Cardiometabolic Risk - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40077646/
Dyslipidemia, characterized by abnormal blood lipid levels, is a major public health concern due to its association with atherosclerotic cardiovascular disease (ASCVD) and other cardiometabolic disorders. In this context, appropriate...
Dyslipidemia management relies on evidence-based nutrition patterns like Mediterranean, plant-based, and high-fiber diets, enriched with bioactive compounds. Combined with lifestyle interventions and nutrigenomics, these approaches improve lipid profiles and cardiovascular outcomes.
1yr
Learnings from Implementation Strategies to Improve Lipid Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39775142/
Implementation studies are heterogenous in their strategies and design. At the clinician level, multidisciplinary team-based care (including multidisciplinary lipid clinics), pharmacist- or nurse-led interventions, decision-support algorithms or protocols, and educational...
This review highlights strategies to optimize lipid management, including team-based care, patient adherence interventions, EHR tools, and telehealth, emphasizing multifaceted approaches and long-term implementation research for sustainable cardiovascular risk reduction.
1yr
Post myocardial infarction patients are usually started on high intensity statin Rx. Followup in office will include following lipid panel. Insurance carrier permitting, an injectable lipid lowering medication can be added if LDL is not below 55, but usually insurance only permits addition of injectables if LDL remains above 70 on high intensity...
1yr
Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40052330/
The clinically important link between LDL cholesterol (LDL - C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines...
Expert consensus highlights LDL-C goal gaps in practice, recommending upfront combination lipid-lowering therapy, including novel agents like bempedoic acid, for high/very high cardiovascular risk and statin-intolerant patients.
1yr
I make sure their lipids are tested and ldl at goal. Many cardiologists expect the pcp to manage ongoing risk factors. Now that psk9 inhibitors are better covered I do add on this therapy to maximum statin and ezetimide if not at goal.
1yr
richard moro many options to get ldl under 55 to prevent recurrence ot intial vascular disease
1yr
ricahard moro there are many options to get ldl to less than 55 in vascular reoccurrence;statins,pck 9 inhibitors benzoic acid to lower cholesterol
1yr
pt with stroles,cva stents and MI's try to maintain ldl chholesterol 55 and ubder with statins,pck9 inhibitors with zetia if needed,also benzoic acid to lower options are available
1yr
Start high intensity statin at the hospital then aggressively titrate it to bring LDLC to less than 55, or add additional medications if not at goal or cannot tolerate a high dose statin
1yr
A landmark study in Lancet Diabetes & Endocrinology identified a T1D subtype in Sub-Saharan African youth and Black Americans lacking islet autoantibodies. This insulin-deficient form isn't autoimmune, urging revised diagnostic, prevention, and treatment strategies.
1yr
Did you know? A randomized crossover trial published in August 2025 demonstrated that a DASH diet modified for type 2 diabetes (DASH4D) significantly improved glycemic control. Adults with T2D on the DASH4D regimen experienced greater reductions in mean CGM glucose and increased time in the target range compared to standard U.S. dietary patterns. Improvements were most pronounced in participants with elevated baseline A1C.
Could evidence-based dietary frameworks like DASH4D enhance existing treatment plans for patients with complex metabolic profiles?
Could evidence-based dietary frameworks like DASH4D enhance existing treatment plans for patients with complex metabolic profiles?
1yr
Lipoprotein(a) and Effects of Diet: Time for Reassessment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40431454/
Dietary modification is a critical tool in the prevention of cardiovascular disease (CVD). While the role of saturated fat (SFA) intake is well established in affecting LDL cholesterol concentrations, diet...
This review explores how diet, particularly saturated fat, sugar, and ketogenic intake, influences lipoprotein(a) concentrations, highlighting genetic interactions, cardiovascular risk implications, and unmet research needs in dietary modulation.
1yr
Patient Background: A 75-year-old woman presents with progressive weight loss, generalized weakness, easy bruising, and poorly controlled hypertension. On exam, she has thin skin with ecchymoses, proximal muscle weakness, and hypokalemia (serum potassium 2.9 mmol/L).
Family History: The patient reported no family history of hormonal disorders, malignancy, or pituitary pathology relevant to her presentation.
Assessment and Diagnosis: Evaluation revealed elevated 24-hour urinary free cortisol (UFC), elevated morning (8 am) serum cortisol, and non-suppression on a low-dose dexamethasone suppression test (LDDST), with elevated ACTH. Pituitary MRI was negative, and Ga-68 DOTATATE PET/CT showed no ectopic lesion. Bilateral inferior petrosal sinus sampling (BIPSS) with CRH stimulation confirmed MRI-negative, ACTH-dependent Cushing’s disease, although features such as marked weight loss and hypokalemia initially raised suspicion for ectopic ACTH secretion.
Suggested treatment plan: The patient declined surgery and opted for medical therapy with an adrenal steroidogenesis inhibitor plus a dopamine agonist.
Patient education: The patient was educated on the importance of medication adherence and avoidance of drug–drug interactions. She was specifically advised to avoid concurrent use of gastric acid–reducing agents, which can impair treatment absorption and effectiveness.
Follow-up: Medical therapy led to normalization of UFC, improved potassium levels, blood pressure, and glycemic control, along with a 15-lb weight gain. A relapse occurred after initiation of an acid-suppressing medication, which compromised drug absorption. Discontinuation restored efficacy, with rapid normalization of hormone levels and a 50-lb weight gain, improving mobility and strength.
- What clinical features in this case suggested ectopic ACTH over typical Cushing’s disease? Answer Severe hypokalemia and marked weight loss suggested ectopic ACTH, unlike the usual weight gain in pituitary Cushing’s disease.
- Given the MRI-negative status, what key test confirmed Cushing’s disease and ruled out ectopic ACTH? Answer Bilateral inferior petrosal sinus sampling (BIPSS) showed a post-CRH central-to-peripheral ACTH ratio >3, confirming a pituitary source of ACTH despite negative imaging.
1yr
Exercise training modestly improves lipid profiles in dyslipidaemia
Dyslipidaemia is a modifiable risk factor for cardiovascular disease (CVD). A large meta-analysis shows that exercise training (ExTr) yields modest but significant improvements across lipid outcomes.
ExTr reduced total cholesterol (−5.9 mg/dL), LDL (−7.2 mg/dL), triglycerides (−8.0 mg/dL), VLDL (−3.9 mg/dL), and increased HDL (+2.1 mg/dL). Combined aerobic training (AT) and resistance training (RT) produced the most consistent lipid improvements. AT alone improved all five markers, while RT primarily raised HDL.
Meta-regression showed dose–response effects: each additional AT session per week was associated with a reduction in TC of −7.7 mg/dL, and longer sessions (>30 minutes) improved HDL. These findings support tailoring exercise to lipid profiles.
ExTr alone may reduce LDL by ~6.3%, corresponding to a potential 4–5% reduction in ASCVD risk. When combined with pharmacologic therapy, total risk reduction may approach 30%.
However, up to 37% of included studies showed no benefit for certain lipid subtypes, underscoring individual variability. Still, 100% of studies reported benefit for VLDL. Exercise should remain a first-line strategy for dyslipidaemia, with tailored prescriptions using AT and RT. AT should be prioritized in cases of hyperlipidaemia.
How will you incorporate these exercise-specific insights into your dyslipidaemia counselling strategies?
1yr
Nutrients Lowering Obesity-Linked Chemokines Blamable for Metastasis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40076892/
Food intake is an essential contributor to both health and disease. Nutrients contribute to a beneficial metabolic equilibrium at the cellular level, preventing or delaying disease onset. Dietary intake contributes...
Obesity-driven inflammation elevates chemokines that promote cancer metastasis. Anti-inflammatory, anti-obesity nutrients like polyphenols, curcumin, and vitamin E may lower chemokine levels, improving cancer outcomes and treatment efficacy.
1yr
Novel Approaches in Glucose and Lipid Metabolism Disorder Therapy: Targeting the Gut Microbiota-Bile Acid Axis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40723361/
Metabolic dysregulation involving glucose and lipids is closely associated with chronic diseases such as type 2 diabetes mellitus. Emerging evidence highlights the regulatory role of bile acid (BA)-gut microbiota interactions...
Bile acid–gut microbiota interactions influence glucose and lipid metabolism via FXR and TGR5 signaling, offering potential therapeutic targets for metabolic disorders like type 2 diabetes and dyslipidemia.
1yr
Healthcare dashboard technologies and data visualization for lipid management: A scoping review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39574106/
Dashboards are important tools in managing lipid disorders in managing lipid disorders, integrating with educational tools, collaborative care models, and decision support systems. Although they are effective in enhancing population...
Dashboard technologies enhance lipid management by supporting prevention, treatment planning, and decision-making, improving population health and clinical workflows, though patient outcomes and cost impacts need further investigation.
1yr
usually aim post mi for LDL less or equal to 55 mg/dl. Often if maxed out on statin add pcsk9i either Repatha or Praluent depending on insurance approval, and make sure nutrition/CDE are consulted before discharge